ANNA-SHARI MELIN is a life sciences lawyer and German Rechtsanwältin. Her practice encompasses a broad range of EU and German regulatory and compliance matters affecting pharmaceutical, biotechnology and medical device companies as well as food, cosmetics, consumer goods and digital health companies. Anna-Shari practices out of Brussels, and works closely with the Munich office on life sciences private equity matters.
Clients benefit from Anna-Shari’s EU and German law practice, in which she brings valuable perspective at the intersection of European and German national law.
Anna-Shari advises clients throughout the product life cycle including analyses and strategy/risk assessments in relation to clinical trials, GMP compliance, early access programs and market access, pharmacovigilance, medicinal product shortages, recalls, the new medical devices regulations, pharmaceutical/device advertising and related compliance. She has represented clients in matters before the European Commission, the European Medicines Agency and numerous Member State authorities, including those in Germany.
In addition to EU and German life sciences regulatory issues, Anna-Shari routinely conducts due diligence on behalf of Sidley’s life sciences clients in connection with mergers and acquisitions, and advises on anti-corruption compliance and government enforcement across Europe and Germany. Anna-Shari has also gathered significant experience in the area of health-related competition law, particularly in connection with pay-for-delay appeals in the EU and the UK.
Prior to joining Sidley, Anna-Shari gained experience at other international law firms in Brussels, as well as in German boutique firms and clerking for German higher regional court and lower court judges.